Ainos, Inc.
Ainos develops artificial intelligence-based scent detection technology and immune therapeutics. Its AI Nose platform combines gas sensor arrays with proprietary AI models to convert scent and volatile organic compound signals into machine-readable Smell ID data. Applications include industrial sensing in semiconductor manufacturing, robotics and smart manufacturing, as well as healthcare monitoring and point-of-care testing devices under development. Ainos targets revenue from AI Nose hardware sales and recurring platform services. It also develops VELDONA, a low-dose oral interferon platform, for selected human and animal health indications, and sells VELDONA Pet supplements in Taiwan. Ainos works with partners on deployments and commercialization, and outsources manufacturing to third parties. It operates research and development and certain other functions primarily in Taiwan. Its wholly owned subsidiary ScentAI focuses on the AI Nose smell language model, while Ainos focuses on hardware, deployment and data generation. Ainos is headquartered in Houston, Texas.
No enriched coverage for $AIMD in the last 7 days.
No SEC Form 4 filings for $AIMD in the last 30 days.
See all $AIMD insider activity →Ainos, Inc. (NASDAQ: AIMD) granted BioPhoenix an exclusive license for its VELDONA platform for two indications, with BioPhoenix funding clinical and regulatory work. The deal has a potential value of $10M, including an initial $600K fee. Ainos retains platform ownership and 25% of sublicensing revenue, aligning with its March strategy.
Ainos, Inc. (AIMD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical Intelligence Initial license payment tied to near-term contractual delivery; additional payment opportunities may arise during development, before drug approval
Ainos, Inc. (NASDAQ: AIMD) reported front-end semiconductor orders, a $2.1M back-end program, and a 1B+ chemical dataset expansion, according to VASRO GmbH. These milestones indicate growing commercial momentum for Ainos' AI Nose platform in semiconductor applications.
Recent AIMD coverage spans technology, corporate actions and earnings.
The licence provides near‑term cash and long‑term upside from sublicensing revenue.
The agreement adds a new revenue stream and reduces capital needs, likely supporting the stock.
The new orders suggest near‑term revenue visibility and could trigger short‑term buying interest.
The new orders signal revenue starting H2 2026 and validate the product’s market adoption.
The update is a positive operational momentum signal, but it is not tied to revenue, margins, or signed commercial milestones in the text.
AlphAI scores every news story that mentions AIMD with an AI model for sentiment and relevance, and aggregates insider trades from Ainos, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ainos, Inc. (NASDAQ: AIMD) granted BioPhoenix an exclusive license for its VELDONA platform for two indications, with BioPhoenix funding clinical and regulatory work. The deal has a potential value of $10M, including an initial $600K fee. Ainos retains platform ownership and 25% of sublicensing revenue, aligning with its March strategy.
2 min readAinos, Inc. (AIMD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical Intelligence Initial license payment tied to near-term contractual delivery; additional payment opportunities may arise during development, before drug approval
2 min readAinos, Inc. (NASDAQ: AIMD) reported front-end semiconductor orders, a $2.1M back-end program, and a 1B+ chemical dataset expansion, according to VASRO GmbH. These milestones indicate growing commercial momentum for Ainos' AI Nose platform in semiconductor applications.
2 min readAinos Inc (AIMD) shares rose 6.9% premarket after receiving initial commercial orders for its AI Nose platform from a semiconductor manufacturer. The orders mark a shift to commercial deployment, with revenue expected from late 2026. The company also announced its real-world chemical dataset surpassed 1 billion records, up from 878 million in August. AIMD's technology is used in semiconductor manufacturing for chemical perception and data collection.
1 min readAinos, Inc. (NASDAQ:AIMD) said its AI Nose platform surpassed 878 million real-world smell and chemical data points, up from about 613 million on July 21, adding about 265 million in 23 days. The company links the growth to continued deployment of 1,400 AI Nose systems at semiconductor customer sites and its ScentAI continuous learning approach.
2 min readAinos, Inc. (NASDAQ:AIMD) said VASRO GmbH published a report on scaling its AI Nose platform. VASRO cited about 613 million industrial Smell ID records accumulated since Dec. 2025 and a $2.1 million AI Nose subscription backlog from a backend semiconductor customer, including $350,000 prepaid. The report points to validation in semiconductor fabs and potential revenue growth in H2 2026.
2 min readAinos, Inc. (NASDAQ:AIMD) reported second-quarter 2026 results for the quarter ended June 30 and updated investors on AI Nose deployments. The company said AI Nose expanded across semiconductor manufacturing, industrial and healthcare infrastructure, and robotics, building smell data. It cited about 613 million industrial smell records accumulated since Dec. 2025, and referenced an initial $2.1 million commercial arrangement.
4 min readAinos, Inc. (AIMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ainos Reports Second Quarter 2026 Results and Highlights Continued AI Nose Execution Across Industrial, Healthcare Infrastructure and Robotics Markets Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (“Ainos” or the “Company”) today announced results for the second quarter en
2 min readAinos, Inc. (NASDAQ:AIMD) said its AI Nose deployments have generated about 613 million industrial scent data points since December 2025, mainly from semiconductor manufacturing. The company says the data supports its Smell AI platform by refining proprietary Smell IDs and its Smell Language Model, and it plans to expand into other industries.
3 min readAinos, Inc. (AIMD) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. false 0001014763 0001014763 2026-07-03 2026-07-03 0001014763 AIMD:CommonStockParValue0.01PerShareMember 2026-07-03 2026-07-03 0001014763 AIMD:WarrantsToPurchaseCommonStockMember 2026-07-03 2026-07-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND E
2 min read